Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
EternaTear logo — Next Generation Artificial Tear for Dry Eye

EternaTear

Next Generation Artificial Tear for Dry Eye

Founded 2018 United States United States 2 employees Series A Total: $4.90M Health Care, Health and Wellness +1

General Information

Company Name EternaTear
Founded Year 2018
Location United States United States
Employees 2
Industries Health Care, Health and Wellness, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with EternaTear. To contact EternaTear, visit eternatear.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About EternaTear

EternaTear is a health care and pharmaceutical startup that aims to revolutionize the treatment of dry eye with its next-generation artificial tear. Founded in 2018 and headquartered in the United States, the company is targeting the lucrative $2 billion over-the-counter dry eye market. EternaTear's recent Series A investment of $4.90M on October 11, 2020 was led by a diverse group of investors including Keiretsu Capital, Band of Angels, Carolina Angel Network, Deepwork Capital, Duke Angel Network, Keiretsu Forum Northwest, and Tom Vorisek. With its innovative approach to addressing a common health issue, EternaTear presents an enticing opportunity for venture capitalists looking to invest in the pharmaceutical and healthcare industries.

Taxonomy: EternaTear, Artificial Tear, Dry Eye, Therapy, Over-the-counter, Market, Innovation, Medical, Start-up, Investment, Pharmaceuticals, Health Technology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $4.90M 7
Keiretsu Capital Band of Angels Carolina Angel Network
Keiretsu Capital, Band of Angels +5
11 Oct 2020
Series A Undisclosed -
04 Oct 2020

EternaTear Alternatives & Competitors

View All Alternatives
EternaTear vs
Surface Pharmaceuticals
Surface Pharmaceuticals

Enhancing ocular health with advanced topical solutions for timely and effective dry eye disease rec...

Venture round
Biopharma, Health Care
EternaTear vs
BMdr
BMdr

Enhancing Vision and Eye Health with Innovative Solutions

Venture round
Health Care, Health and Wellness
EternaTear vs
MAXWELLIA
MAXWELLIA United Kingdom

Widening access to medicines

10 employees
Biopharma, Health Care
View all alternatives

FAQ About EternaTear

Next Generation Artificial Tear for Dry Eye
EternaTear was founded in 2018.
EternaTear is headquartered in United States.
EternaTear operates in Health Care, Health and Wellness and Pharmaceutical. Its work centres on EternaTear, Artificial Tear, Dry Eye and Therapy.
EternaTear has approximately 2 employees.
EternaTear has completed 2 funding rounds, raising a total of $4.90M. The latest funding stage is Series A.
Top alternatives and competitors to EternaTear include Surface Pharmaceuticals, BMdr, MAXWELLIA, Mapaex, ForSight VISION5 (now Allergan). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EternaTear and Surface Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EternaTear, https://bouncewatch.com/company/eternatear, updated 2 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes